Abstract
β2 agonists and anticholinergics are two major classes of bronchodilators which form first line of drugs recommended in symptomatic treatment of asthma and COPD. Combinational therapy involving β agonists and anticholinergics prove more effective in treating airway disease than use of either agent alone. In present investigation, binding modes of Muscarinic Antagonism and β 2 Agonism (MABA) conjugates designed by Lyn et al. were revealed on structural grounds adopting molecular docking techniques. The conjugates tether β 2 motif onto M3 motif which makes it a single molecule that acts as both β 2 agonist and antimuscarinic agent. Series of conjugates were docked against β 2 adrenergic receptor and modeled M3 muscarinic acetylcholine receptor and pharmacophoric features were identified. Upon screening the conjugates on the basis of receptor ligand free energy, hydrogen bonding and internal electrostatic interaction, conjugate 11 demonstrated superior interactions with the receptors compared to remaining conjugates in the series. While, in vitro results and in silico outcomes are in agreement to reveal that conjugate 11 to possess best pharmacological profile, binding modes obtained in docking can be utilized to design new conjugates with improved biological activity. A close study of receptor residues in binding site and atoms, groups and substructures of conjugates may be used to develop favourable secondary valence forces towards receptor-ligand interactions.
Keywords: Chronic obstructive pulmonary disease (COPD), asthma, bronchodilators, muscarinic antagonism and β 2 agonism (MABA) conjugates, comparative modeling, molecular docking, pharmacophore identification.
Current Topics in Medicinal Chemistry
Title:Binding Modes and Pharmacophoric Features of Muscarinic Antagonism and β2 Agonism (MABA) Conjugates
Volume: 13 Issue: 14
Author(s): Srinivas Bandaru, M. Hema Prasad, A. Jyothy, Anuraj Nayarisseri and Mukesh Yadav
Affiliation:
Keywords: Chronic obstructive pulmonary disease (COPD), asthma, bronchodilators, muscarinic antagonism and β 2 agonism (MABA) conjugates, comparative modeling, molecular docking, pharmacophore identification.
Abstract: β2 agonists and anticholinergics are two major classes of bronchodilators which form first line of drugs recommended in symptomatic treatment of asthma and COPD. Combinational therapy involving β agonists and anticholinergics prove more effective in treating airway disease than use of either agent alone. In present investigation, binding modes of Muscarinic Antagonism and β 2 Agonism (MABA) conjugates designed by Lyn et al. were revealed on structural grounds adopting molecular docking techniques. The conjugates tether β 2 motif onto M3 motif which makes it a single molecule that acts as both β 2 agonist and antimuscarinic agent. Series of conjugates were docked against β 2 adrenergic receptor and modeled M3 muscarinic acetylcholine receptor and pharmacophoric features were identified. Upon screening the conjugates on the basis of receptor ligand free energy, hydrogen bonding and internal electrostatic interaction, conjugate 11 demonstrated superior interactions with the receptors compared to remaining conjugates in the series. While, in vitro results and in silico outcomes are in agreement to reveal that conjugate 11 to possess best pharmacological profile, binding modes obtained in docking can be utilized to design new conjugates with improved biological activity. A close study of receptor residues in binding site and atoms, groups and substructures of conjugates may be used to develop favourable secondary valence forces towards receptor-ligand interactions.
Export Options
About this article
Cite this article as:
Bandaru Srinivas, Prasad Hema M., Jyothy A., Nayarisseri Anuraj and Yadav Mukesh, Binding Modes and Pharmacophoric Features of Muscarinic Antagonism and β2 Agonism (MABA) Conjugates, Current Topics in Medicinal Chemistry 2013; 13 (14) . https://dx.doi.org/10.2174/15680266113139990115
DOI https://dx.doi.org/10.2174/15680266113139990115 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Applications of Michael Addition Reaction in Organic Synthesis
Current Organic Synthesis State of the Art and Perspectives in Food Allergy (Part I): Diagnosis
Current Pharmaceutical Design Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Preface:
Drug Metabolism Letters Therapies in Development for Non-Infectious Uveitis
Current Molecular Medicine New Insights into the Modulation of Immune Response by Fasciola hepatica Excretory-Secretory Products
Current Immunology Reviews (Discontinued) Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Current Pharmaceutical Design Macrolides Allergy
Current Pharmaceutical Design Treatment with Paracetamol is not Associated with Increased Airway Sensitivity and Risk of Asthma in Rats
Current Drug Safety New Applications for Sublingual Immunotherapy in Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry Clinical Analysis Methods of Voice Disorders
Current Bioinformatics Emergence of Pharmacogenomics in Academic Medicine and Public Health in Jordan: History, Present State and Prospects
Current Pharmacogenomics and Personalized Medicine Angiopoietin-1 and C16 Peptide Attenuate Vascular and Inflammatory Responses in Experimental Allergic Encephalomyelitis
CNS & Neurological Disorders - Drug Targets A Conceptual Framework of Comorbidity for Investigation in the Context of Psychiatric Disturbance
Current Psychiatry Reviews Advances in Developing Prophylactics and Therapeutics to Counter Inflammatory, Allergic and Infectious Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Meet Our Editor
Current Metabolomics From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design A Novel Support Vector Machine Classifier Using Soft Computing Approach for Automated Classification of Emphysema, Bronchiectasis and Pleural Effusion Using Optimized Gabor Filter
Current Signal Transduction Therapy Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management
Current Diabetes Reviews